Skip to main content

Table 2 Lesion characteristics and treatment parameters

From: Stereotactic radiosurgery combined with targeted/ immunotherapy in patients with melanoma brain metastasis

ParameterNumber of lesions absolute relative
Number of lesions with follow up ≥3 months52100%
Location of metastasis
 Left2650.0%
 Right2548.1%
 Midline11.9%
 Frontal1936.5%
 Parietal611.5%
 Temporal815.4%
 Occipital611.5%
 Frontotemporal11.9%
 Temporoparietal11.9%
 Parietooccipital11.9%
 Cerebellum35.8%
 Others (basal ganglia, insular cortex, parahippocampal, parafalcin)713.5%
GTV to PTV margin (mm)
 2 mm2446.2%
 3 mm2853.8%
Prescribed dose (Gy)
 1511.9%
 1723.8%
 181732.7%
 203057.7%
 2423.8%
Prescribed isodose (%)
 7011.9%
 805198.1%
Treatment planning software
 Oncentra Masterplan3057.7%
 Monaco1732.7%
 Radionics59.6%
Fixation technique
 Frameless Brainlab mask917.3%
 Frameless double thermoplastic mask3873.1%
 Invasive fixed head frame59.6%
Targeted/ immunotherapy (TT/IT)
 BRAFi59.6%
 MEKi11.9%
 Anti-CTLA-447.7%
 Anti-PD11426.9%
 BRAFi+MEKi611.5%
 Anti-PD1 + Anti-CTLA-41019.2%
 Triple combination23.8%
 none1019.2%
Application of TT/IT
 Before SRS (median: 9.5 days, range: 3-43 days)2446.2%
 Concurrent before SRS (median: 8 days, range: 3–21 days)2140.4%
 After SRS (median: 9 days, range: 2–97 days)3975.0%
 Concurrent after SRS (median: 8 days, range: 2–27 days)1528.8%
 Concurrent (4 weeks before or 4 weeks after SRS)3669.2%